Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9855221 | INDIVIOR INC | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
Feb, 2022
(1 year, 7 months ago) | |
US9931305 | INDIVIOR INC | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions |
Feb, 2022
(1 year, 7 months ago) | |
US10285910 | INDIVIOR INC | Sublingual and buccal film compositions |
Oct, 2022
(11 months ago) | |
US8017150 | INDIVIOR INC | Polyethylene oxide-based films and drug delivery systems made therefrom |
Feb, 2023
(7 months ago) | |
US8603514 | INDIVIOR INC | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions |
Apr, 2024
(6 months from now) | |
US11135216 | INDIVIOR INC | Sublingual and buccal film compositions |
Aug, 2029
(5 years from now) | |
US9687454 | INDIVIOR INC | Sublingual and buccal film compositions |
Aug, 2029
(5 years from now) | |
US8475832 | INDIVIOR INC | Sublingual and buccal film compositions |
Mar, 2030
(6 years from now) |
Suboxone is owned by Indivior Inc.
Suboxone contains Buprenorphine Hydrochloride; Naloxone Hydrochloride.
Suboxone has a total of 8 drug patents out of which 4 drug patents have expired.
Expired drug patents of Suboxone are:
Suboxone was authorised for market use on 30 August, 2010.
Suboxone is available in film;buccal, sublingual dosage forms.
Suboxone can be used as treating opioid use disorder, treatment of opioid dependence/sublingual or buccal application, this drug is administered by sublingual route to humans for maintenance treatment of opioid dependence.
The generics of Suboxone are possible to be released after 26 March, 2030.
Drugs and Companies using BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 30 August, 2010
Treatment: Treatment of opioid dependence/sublingual or buccal application; Treating opioid use disorder; This drug is administered by sublingual route to humans for maintenance treatment of opioid dependence
Dosage: FILM;BUCCAL, SUBLINGUAL
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic